Search research articles
Contact Us
Filters
Showing results (1-10 of 12) with videos related to
Page
of 2
Sort By:
Physical Medicine and Rehabilitation Clinics of North America
|
September 6, 2006
Soccer
Melvin R Manning, Richard S Levy
Leukemia Research
|
May 21, 2013
Progressive burden of myelofibrosis in untreated patients: assessment of patient-reported outcomes in patients randomized to placebo in the COMFORT-I study
Ruben A Mesa, Alan Shields, Thomas Hare, et al.
Oncotargets and Therapy
|
December 26, 2013
Management of cytopenias in patients with myelofibrosis treated with ruxolitinib and effect of dose modifications on efficacy outcomes
Srdan Verstovsek, Jason Gotlib, Vikas Gupta, et al.
Blood
|
November 1, 2013
Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis
Francisco Cervantes, Alessandro M Vannucchi, Jean-Jacques Kiladjian, et al.
British Journal of Haematology
|
May 16, 2013
Health-related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy
Claire N Harrison, Ruben A Mesa, Jean-Jacques Kiladjian, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 21, 2013
Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial
Ruben A Mesa, Jason Gotlib, Vikas Gupta, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 10, 2015
Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has Failed
Herbert I Hurwitz, Nikhil Uppal, Stephanie A Wagner, et al.
Journal of Hematology & Oncology
|
November 29, 2013
Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts
Moshe Talpaz, Ronald Paquette, Lawrence Afrin, et al.
Haematologica
|
January 25, 2015
Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I
Srdan Verstovsek, Ruben A Mesa, Jason Gotlib, et al.
British Journal of Haematology
|
March 14, 2013
The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosis
Srdan Verstovsek, Ruben A Mesa, Jason Gotlib, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 12) with videos related to
Sort By:
Page
of 2
Physical Medicine and Rehabilitation Clinics of North America
|
September 6, 2006
Soccer
Melvin R Manning, Richard S Levy
Leukemia Research
|
May 21, 2013
Progressive burden of myelofibrosis in untreated patients: assessment of patient-reported outcomes in patients randomized to placebo in the COMFORT-I study
Ruben A Mesa, Alan Shields, Thomas Hare, et al.
Oncotargets and Therapy
|
December 26, 2013
Management of cytopenias in patients with myelofibrosis treated with ruxolitinib and effect of dose modifications on efficacy outcomes
Srdan Verstovsek, Jason Gotlib, Vikas Gupta, et al.
Blood
|
November 1, 2013
Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis
Francisco Cervantes, Alessandro M Vannucchi, Jean-Jacques Kiladjian, et al.
British Journal of Haematology
|
May 16, 2013
Health-related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy
Claire N Harrison, Ruben A Mesa, Jean-Jacques Kiladjian, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 21, 2013
Effect of ruxolitinib therapy on myelofibrosis-related symptoms and other patient-reported outcomes in COMFORT-I: a randomized, double-blind, placebo-controlled trial
Ruben A Mesa, Jason Gotlib, Vikas Gupta, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 10, 2015
Randomized, Double-Blind, Phase II Study of Ruxolitinib or Placebo in Combination With Capecitabine in Patients With Metastatic Pancreatic Cancer for Whom Therapy With Gemcitabine Has Failed
Herbert I Hurwitz, Nikhil Uppal, Stephanie A Wagner, et al.
Journal of Hematology & Oncology
|
November 29, 2013
Interim analysis of safety and efficacy of ruxolitinib in patients with myelofibrosis and low platelet counts
Moshe Talpaz, Ronald Paquette, Lawrence Afrin, et al.
Haematologica
|
January 25, 2015
Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I
Srdan Verstovsek, Ruben A Mesa, Jason Gotlib, et al.
British Journal of Haematology
|
March 14, 2013
The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, Phase III study in patients with myelofibrosis
Srdan Verstovsek, Ruben A Mesa, Jason Gotlib, et al.
Page
of 2